John Newcomer

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 69:1046-56. 2008
  2. ncbi request reprint Metabolic considerations in the use of antipsychotic medications: a review of recent evidence
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 68:20-7. 2007
  3. ncbi request reprint Antipsychotic medications: metabolic and cardiovascular risk
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:8-13. 2007
  4. doi request reprint Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 70:30-6. 2009
  5. ncbi request reprint Severe mental illness and risk of cardiovascular disease
    John W Newcomer
    Department of Psychiatry, and the Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 298:1794-6. 2007
  6. pmc A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    J Clin Psychiatry 70:487-99. 2009
  7. ncbi request reprint Metabolic syndrome and mental illness
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110, USA
    Am J Manag Care 13:S170-7. 2007
  8. pmc Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine
    John W Newcomer
    Department of Psychiatry, and Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    Schizophr Res 106:300-7. 2008
  9. ncbi request reprint Medical risk in patients with bipolar disorder and schizophrenia
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 67:e16. 2006
  10. ncbi request reprint Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care
    Henry A Nasrallah
    Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center in Cincinnati, OH 45267 0559, USA
    J Clin Psychopharmacol 24:S7-14. 2004

Research Grants

  1. Metabolic Effects of Antipsychotics in Children
    John Newcomer; Fiscal Year: 2007
  2. Antipsychotic Medication
    John Newcomer; Fiscal Year: 2005
  3. GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS
    John Newcomer; Fiscal Year: 2003
  4. Metabolic Effects of Antipsychotics in Children
    John W Newcomer; Fiscal Year: 2010

Detail Information

Publications47

  1. ncbi request reprint A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 69:1046-56. 2008
    ..This multicenter, randomized, double-blind study compared the metabolic effects of aripiprazole versus olanzapine in overweight persons with schizophrenia or schizoaffective disorder who were previously on olanzapine treatment...
  2. ncbi request reprint Metabolic considerations in the use of antipsychotic medications: a review of recent evidence
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 68:20-7. 2007
    ....
  3. ncbi request reprint Antipsychotic medications: metabolic and cardiovascular risk
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:8-13. 2007
    ..Various strategies for monitoring cardiometabolic risk factors in patients with mental illness are discussed in this review...
  4. doi request reprint Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 70:30-6. 2009
    ..Therefore, clinicians involved in the care of this patient population should screen and monitor carefully for cardiometabolic side effects and risk factors...
  5. ncbi request reprint Severe mental illness and risk of cardiovascular disease
    John W Newcomer
    Department of Psychiatry, and the Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 298:1794-6. 2007
  6. pmc A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    J Clin Psychiatry 70:487-99. 2009
    ..This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone...
  7. ncbi request reprint Metabolic syndrome and mental illness
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110, USA
    Am J Manag Care 13:S170-7. 2007
    ..This article provides an overview of cardiometabolic risk in patients with major mental illness and describes steps for risk reduction...
  8. pmc Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine
    John W Newcomer
    Department of Psychiatry, and Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    Schizophr Res 106:300-7. 2008
    ..This post-hoc analysis assessed changes in these parameters during treatment with the atypical antipsychotics olanzapine or aripiprazole using pooled data from three randomized, long-term clinical studies in patients with schizophrenia...
  9. ncbi request reprint Medical risk in patients with bipolar disorder and schizophrenia
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 67:e16. 2006
    ....
  10. ncbi request reprint Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care
    Henry A Nasrallah
    Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center in Cincinnati, OH 45267 0559, USA
    J Clin Psychopharmacol 24:S7-14. 2004
    ..As clinicians refine practice patterns regarding the atypical antipsychotics, they may require additional knowledge and resources to fully incorporate risk/benefit considerations and optimize long-term psychiatric and medical outcomes...
  11. ncbi request reprint Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  12. ncbi request reprint Abnormalities in glucose regulation associated with mental illness and treatment
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    J Psychosom Res 53:925-33. 2002
  13. ncbi request reprint Identifying metabolic risks with antipsychotics and monitoring and management strategies
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:e17. 2007
    ..Because of the possibility that some antipsychotic treatments can lead to weight gain and metabolic changes and possibly to severe physical illness, regular physical checks should be made...
  14. ncbi request reprint Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
    ..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
  15. ncbi request reprint Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Neuropsychopharmacology 32:2561-9. 2007
    ..Adiposity levels occurring during antipsychotic treatment are strongly related to insulin resistance, confirming that antipsychotic-induced weight gain can contribute to increased cardiometabolic risk in this population...
  16. ncbi request reprint Medical risk in patients with bipolar disorder and schizophrenia
    John W Newcomer
    Department of Psychiatry, Psychology, and Medicine, and the Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 67:25-30; discussion 36-42. 2006
    ....
  17. ncbi request reprint The metabolic effects of antipsychotic medications
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Can J Psychiatry 51:480-91. 2006
    ....
  18. ncbi request reprint Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
    CNS Spectr 10:suppl14 1-15. 2005
    ....
  19. ncbi request reprint Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    CNS Drugs 19:1-93. 2005
    ....
  20. ncbi request reprint Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
    ..While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity...
  21. doi request reprint A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
    J Clin Psychopharmacol 30:425-30. 2010
    ....
  22. doi request reprint Best practices: implementation of a glucose screening program based on diffusion of innovation theory methods
    Ginger E Nicol
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8134, St Louis, MO 63110, USA
    Psychiatr Serv 62:12-4. 2011
    ..This column describes the successful implementation of a best-practice glucose screening program in a large network of community mental health centers that was based on Six Sigma and diffusion of innovation theory...
  23. ncbi request reprint The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists
    John W Newcomer
    Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychopharmacol 24:S1-6. 2004
    ..The impact of additional data and educational efforts in this area, such as a recently published consensus statement from the American Diabetes Association and other organizations, remains to be assessed...
  24. ncbi request reprint Plasma leptin and adiposity during antipsychotic treatment of schizophrenia
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Neuropsychopharmacology 30:184-91. 2005
    ..The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications...
  25. doi request reprint Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Am J Psychiatry 166:345-53. 2009
    ....
  26. pmc Addressing cardiometabolic risk during treatment with antipsychotic medications
    Jonathan M Amiel
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York 10032, USA
    Curr Opin Psychiatry 21:613-8. 2008
    ..To raise awareness of and inform evidence-based practice regarding medical and behavioral interventions for antipsychotic medication-induced metabolic abnormalities...
  27. ncbi request reprint Abnormalities of glucose metabolism associated with atypical antipsychotic drugs
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Psychiatry 65:36-46. 2004
    ..The purpose of this article is to review the association between antipsychotic medications and obesity, insulin resistance, and diabetes, including the mechanisms through which these changes might be effected...
  28. ncbi request reprint Metabolic risk during antipsychotic treatment
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Clin Ther 26:1936-46. 2004
    ....
  29. ncbi request reprint Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients
    Peter L Zhang
    BJC Behavioral Health Clinics, 1430 Olive St, Saint Louis, MO 63110, USA
    Schizophr Res 71:137-44. 2004
    ....
  30. ncbi request reprint Integrating general health care in private community psychiatry practice
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    J Clin Psychiatry 68:e19. 2007
    ....
  31. ncbi request reprint Monitoring and managing weight gain in the mentally ill
    Rohan Ganguli
    Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Psychiatry 68:e14. 2007
  32. ncbi request reprint Comparing safety and tolerability of antipsychotic treatment
    John W Newcomer
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:e07. 2007
    ..The principals of primary prevention suggest the importance of lowering risk for disease by using monitoring and intervention approaches...
  33. ncbi request reprint Does cognitive function improve with quetiapine in comparison to haloperidol?
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, M S 7792, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    Schizophr Res 53:239-48. 2002
    ....
  34. ncbi request reprint Introduction: cardiovascular disease and metabolic risk factors in patients with mental illness
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, St Louis, Missouri, USA
    CNS Spectr 13:1-14. 2008
  35. ncbi request reprint Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    CNS Spectr 13:13-4. 2008
  36. ncbi request reprint Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype
    Suzanne Craft
    Geriatric Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA
    Psychoneuroendocrinology 28:809-22. 2003
    ....
  37. ncbi request reprint Managing psychosis in long-term care: treating the whole patient
    Pierre N Tariot
    J Am Med Dir Assoc 4:H2-7. 2003
  38. ncbi request reprint Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004
  39. ncbi request reprint Effects of glucocorticoids on declarative memory function in major depression
    J Douglas Bremner
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 126 Briarcliff Road, Atlanta, GA 30306, USA
    Biol Psychiatry 55:811-5. 2004
    ..The purpose of this study was to assess the effects of the glucocorticoid, dexamethasone, on verbal declarative memory function in patients with untreated unipolar major depressive disorder (MDD)...
  40. ncbi request reprint From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  41. ncbi request reprint Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    J Clin Psychiatry 69:514-9. 2008
    ....
  42. ncbi request reprint Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data
    Elaine H Morrato
    Department of Pediatrics, School of Medicine, University of Colorado at Denver, Aurora, CO 80045 0508, USA
    J Clin Psychiatry 69:316-22. 2008
    ..This study aimed to determine the prevalence of serum glucose and lipid monitoring in public mental health clients initiating second-generation antipsychotic (SGA) drugs...
  43. ncbi request reprint Series introduction and cardiovascular disease in patients with schizophrenia
    Charles H Hennekens
    Center of Excellence and Department of Biomedical Science, Florida Atlantic University, Boca Raton, Fla, USA
    J Clin Psychiatry 68:e12. 2007
  44. ncbi request reprint Evidence of switching antipsychotic therapy to improve metabolic disturbances
    Peter J Wieden
    Department of Psychiatry and the Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, NY, USA
    J Clin Psychiatry 68:e13. 2007
  45. ncbi request reprint Effects of dexamethasone on declarative memory function in posttraumatic stress disorder
    J Douglas Bremner
    Departments of Psychiatry and Behavioral Sciences and Radiology, Emory Center for Positron Emission Tomography, Emory University School of Medicine, Atlanta 30306 GA, USA
    Psychiatry Res 129:1-10. 2004
    ....
  46. ncbi request reprint Challenges and solutions to integrating mental and physical health care
    Benjamin G Druss
    Department of Health Policy Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA
    J Clin Psychiatry 68:e09. 2007
    ....
  47. ncbi request reprint Implementing evidence-based medicine: lessons from public mental health settings
    Joseph J Parks
    University of Missouri Columbia and the Department of Mental Health, State of Missouri, Jefferson City, USA
    J Clin Psychiatry 68:e16. 2007

Research Grants14

  1. Metabolic Effects of Antipsychotics in Children
    John Newcomer; Fiscal Year: 2007
    ..Relevant data are critically needed to assess the risks of antipsychotic therapy in children, to identify targets for additional basic research, and to guide clinical decision-making. ..
  2. Antipsychotic Medication
    John Newcomer; Fiscal Year: 2005
    ..Relevant data is critically needed to target basic research, identify long-term cardiovascular consequences, and plan therapeutic interventions. ..
  3. GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS
    John Newcomer; Fiscal Year: 2003
    ..g., GC receptor antagonists, calcium channel blockers) for preventing this adverse effect on memory. ..
  4. Metabolic Effects of Antipsychotics in Children
    John W Newcomer; Fiscal Year: 2010
    ..Relevant data are critically needed to assess the risks of antipsychotic therapy in children, to identify targets for additional basic research, and to guide clinical decision-making. ..